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3Abstract 
Background: Recent published studies have shown meaningful discrepancies 
between local investigator and blinded, independent, central review (BICR) assessed 
median progression-free survival (PFS). When the local review but not BICR shows 
progression, generally, no further assessments are performed and patients are 
censored in the BICR analysis, leading to violation of the statistical assumptions of 
independence between censoring and outcome used in survival analysis methods.
Methods: We performed a simulation study to assess methodological reasons 
behind these discrepancies and corroborated our findings in a case study of three 
BRCA-mutated ovarian cancer trials. We briefly outline possible methodological 
solutions that may lead to improved estimation of the BICR medians.
Results: The Kaplan-Meier curve for the BICR PFS can often be exaggerated. The 
degree of bias is largest when there is reasonably strong correlation between BICR 
and local PFS, especially when PFS is long compared to assessment frequency. 
This can result in an exaggeration of the medians and their difference; however, the 
hazard ratio (HR) is much less susceptible to bias. Our simulation shows that when 
the true BICR median PFS was 19 months, and patients assessed every 12 weeks, 
the estimated Kaplan-Meier curves were materially biased whenever the correlation 
between BICR and local PFS was 0.4 or greater. This was corroborated by case 
studies where, in the active arm, the BICR median PFS was between 6 and 11 
months greater than the local median PFS. Further research is required to find 
improved methods for estimating BICR survival curves.
4Conclusions: In general, when there is a difference between local and BICR 
medians, the true BICR Kaplan-Meier curve is likely to be exaggerated and its true 
median will probably lie somewhere between the observed local and BICR medians.
Presentation of data should always include both BICR and local results whenever a 
BICR is performed.
Word count: 299 (300 words or fewer)
5Introduction
Progression-free survival (PFS) is an accepted measure of clinical activity and an 
effect on PFS may also be regarded as a clinical benefit if the magnitude of effect is 
sufficiently large. Increasingly, it is used as a registration endpoint, especially when 
post-progression survival is long or confounded by post-progression treatment.
Therefore, it is imperative that the size of any benefit is accurately represented.
Unlike overall survival, the date of progression is not known exactly, only that it occurs 
within an interval between two successive scans. As a result, there are a number of 
additional methodological considerations when analysing PFS. These include the 
need for identical timing of scans between arms, pre-defined censoring rules for the 
handling of patients who take other anti-cancer therapy prior to progression or PFS 
events that occur after a number of missed assessments. These issues have been 
described by a number of authors [1–3]. 
While objective criteria, such as response evaluation criteria in solid tumours 
(RECIST) [4], are routinely used to decide when a patient has progressed 
radiologically, there can be high levels of disagreement between readers, which has 
the potential to cause bias in the estimated treatment effect. This is often called 
ascertainment bias and has driven the requirement to have scans read by a central 
group of radiologists who are blinded to treatment arm, the local investigator 
assessment of progression and other clinical outcomes. This is commonly referred to 
as a blinded, independent, central review (BICR).
It would be natural to expect that the treatment effects estimated using the BICR-
derived PFS would result in an unbiased estimate of outcome in each arm. This may 
6largely be the case when assessing response rate; however, for PFS there are special 
issues related to censoring [5]. When the treating physician (local assessment) 
determines that the patient has progressed, sometimes on the basis of clinical events 
not visible to the BICR readers, no further scans are normally performed. In the 
analysis of BICR progression, if the central reviewer does not believe the patient has 
progressed, they are censored at the time of the local progression. This applies 
regardless of whether the data are analysed using the log-rank test or Cox model or 
presented using a Kaplan-Meier (KM) curve. With the advent of immunotherapy
protocols increasingly requesting a confirmatory scan of progression [6], this design 
feature only partially offsets the issues described here.
A positive correlation between the true local and BICR PFS times leads to a level of 
agreement between local and BICR reviewers that is usually higher than would be 
expected due to chance. This violates the statistical assumptions of independence 
between censoring and outcome used in survival analysis methods. This type of 
censoring is often termed informative [5]. 
A number of authors have assessed whether the presence of informative censoring 
biases the hazard ratio (HR), the primary measure of treatment effect. Separate meta-
analyses of double-blind and open-label studies have shown that in general local and 
BICR PFS HRs are highly consistent [7,8]. Therefore, in the case of the estimation of 
the HR, non-differential informative censoring may not necessarily result in material 
bias even when discordance rates are as high as 50% [9]. However, simulation studies 
have identified that, for individual studies, if there is a between-arm difference in the 
proportion of local PFS times earlier than BICR, there is likely to be bias in the estimate 
of the HR [10–12]. 
7HRs are not the only measures used to describe and gauge the extent of clinical 
benefit; KM estimates of medians are also routinely presented. There are many issues 
with the use of a median to describe an average outcome of a treatment arm: it can 
understate benefit if the treatment effect is delayed or overstate benefit when the 
treatment effect wanes with longer follow-up. For PFS, the median has additional 
problems due to the stepped nature of the KM curves. These steps may randomly just 
fall short, or just pass the 50th percentile and consequently, the medians may 
substantially either over- or underestimate the true value, especially if the numbers at 
risk are relatively small. Despite these problems, and in the absence of a universally 
accepted alternative, medians are still routinely used in labelling and their difference 
used as an important measure of clinical benefit. Therefore, the impact of informative 
censoring on the KM curve of PFS needs to be clearly understood. The same 
considerations also apply to other measures taken from the KM curves, such as mean 
survival or landmark times, for example, the proportion of patients progression-free at 
1 year.
Here, we present a simulation study and a case study in ovarian cancer from a series 
of related trials. We also briefly introduce possible alternatives to analysis, but these 
require further in-depth assessment and we hope this paper stimulates further 
research.
8Simulation 
We performed a simulation study in which each patient was assumed to have 
exponentially distributed progression times for the BICR and local review, which were 
aligned to assessments every 12 weeks and with varying levels of correlation. Full 
details of the methodology are provided in the supplementary appendix and expanded 
upon below Table 2.
When there was truly no difference in the true local and BICR PFS medians, the 
observed BICR survival curve and consequently median can be exaggerated. The 
presence and extent of bias depended on the correlation between local and BICR PFS 
times and how frequently patients were assessed prior to progression (Table 1). When 
the true BICR median PFS was 19 months, and with patients assessed every 
12 weeks, the Kaplan-Meier curves were materially biased whenever the correlation 
between BICR and local PFS times was 0.4 or greater. The median was exaggerated 
on average by 5.8 months when the correlation was 0.9, with the bias applying to the 
entire KM curve (Figure 1). In contrast, when the true BICR median was 6 months, 
and with an assessment frequency of 12 weeks, the extent of bias was much lower
and unlikely to be apparent. Our simulations also confirm previous findings that the 
HR is much less susceptible to bias.
Further simulation results are provided in the supplementary appendix, which describe 
the extent of bias with the same assessment frequency but with medians of 9, 12 and 
14 months and situations where the true local and BICR PFS medians differed.
9Case study in BRCA-mutated ovarian cancer
We examined three closely related maintenance trials of poly-ADP ribose polymerase 
inhibitors (PARPis) olaparib, niraparib and rucaparib in platinum-sensitive ovarian 
cancer [13–15]. The patient populations, endpoint definitions and assessment 
frequencies were highly consistent between trials (supplementary appendix). For the 
niraparib and rucaparib trials we present data from only the BRCA-mutated subgroups;
however, the pattern of findings in the non-BRCA subgroups is consistent with the 
BRCA-mutated groups. The olaparib trial only recruited BRCA-mutated patients.
While the treatment effect, as measured by the HR, is similar regardless of whether 
the scans were reviewed locally or by BICR, the KM estimates of the PARPi arm 
median vary greatly (Table 2, Figure 2). In these trials the BICR median is between 6 
and 11 months longer than the local median in the treatment arm. In the placebo arm, 
where fewer assessments were performed prior to progression, there is no such 
difference in the medians. Furthermore, the difference in medians between-arm is also 
much greater, 67%–91%, on the BICR review compared to the local review.
These findings are consistent with the simulation study. Therefore, given that the HRs 
are broadly similar between the local and BICR assessment, this suggests that the 
true increase in PFS, as measured by BICR, probably lies somewhere between that 
observed and that measured by the local review.
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Alternative methods
If current approaches to the estimation of survival curves for BICR data are inadequate,
what alternatives exist? There has been little attention paid to this topic in the statistical 
literature but some possible solutions exist that were designed for related situations.
The performance of these methods will however require further scrutiny before any 
preferred approach can be chosen. We summarise the options here.
One approach is to impute a BICR event at the next scheduled visit every time a 
progression is called only by the investigator. Indeed, this approach was applied by 
the US Food and Drug Administration (FDA) as a sensitivity in the review of niraparib 
and olaparib [16, 17]. When applied to the SOLO2 and NOVA trials, the estimated 
BICR medians were 19.6 m and 5.5 m for the olaparib and placebo arms respectively 
[17], and 13.6 m vs 5.4 m [16] for the niraparib and placebo arms respectively.
However, while such a sensitivity analysis is helpful to assess for possible bias with 
the HR, our simulations show that they can greatly underestimate the true BICR 
median (supplementary appendix), especially when patients are assessed multiple 
times prior to progression. Therefore, a more sophisticated approach is probably 
needed to get closer to the true median value.
Of the published methods, one possible alternative approach is to apply the inverse 
probability of censoring weights (IPCW) method [18]. This is often used to estimate 
overall survival in trials where patients in the control arm switch to experimental 
therapy. A related, multiple imputation method [19], could also be applied in this 
situation. In this approach, patients with local-only progression are matched with other 
patients who most resemble them and their outcomes are randomly imputed. 
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Discussion
We have shown that KM estimates of the BICR PFS survival curve can be 
exaggerated even when the local and true BICR curves are identical – methodological 
bias. The exaggeration is most evident when the median PFS is a large multiple of the 
assessment frequency and there is a reasonable correlation between the local and 
BICR PFS times. In the SOLO2 trial, we estimated this correlation to be in excess of 
0.9, using a joint-modelling approach. In the simulations, when median PFS was more 
than five times the assessment frequency, the median was falsely extended by at least 
2 months, as long as the correlation was larger than 0.6. In some scenarios, it was 
shown that median BICR PFS might be exaggerated by as much as 6 months solely 
due to methodological bias. In contrast, when the median was twice the assessment 
frequency or less, the extent of bias was negligible. Perhaps surprisingly, scanning 
patients more frequently does little to improve power [2], so these findings provide 
another reason to apply the same scanning frequency in trials as used in clinical 
practice. The source of the bias in the BICR median is the handling of patients with 
local-only progression in standard analyses. This explains why bias is greatest when 
patients are assessed more often relative to their rate of progression as there is a 
higher chance of a disagreement in progression status between visits.
A case study of maintenance trials in BRCA-mutated platinum-sensitive ovarian 
cancer corroborated the findings of the simulation study. This general pattern also 
seems to be replicated in other situations where other highly active therapies have 
been studied, such as CDK4/6 inhibitors in advanced breast cancer; the median BICR 
vs local PFS was 22.4 vs 16.4 and 30.5 vs 24.8 for the active arms of trials of 
abemociclib [20], palbociclib [21], respectively.
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Having identified the circumstances where there is the greatest potential for bias, how 
would we know whether this applies to a particular trial? Our research suggests there 
is no universal threshold of a single observable metric of discordance rates between 
the local and BICR assessments that would identify whether or not methodological 
bias was present. However, given that relatively, the HR is not susceptible to 
methodological bias, it could be used to gauge the extent to which an extended BICR 
median is real. For example, if the HRs are reasonably consistent, as they were in the 
case studies, if the BICR PFS is longer than the local PFS only in the arm with longest 
PFS, it would suggest the BICR Kaplan-Meier curves and hence median is biased and 
its true value lies somewhere between the two.
We have focused on quantifying the bias in the estimation of the median because it is 
routinely presented. As a measure of average benefit, it has many problems, one of 
which was highlighted in the case study. When applied to PFS, in a well conducted 
trial, using standard analysis approaches, the KM curve will have clearly defined steps, 
the location of which can have a large bearing on the estimated median. For both 
olaparib and niraparib the KM curve just failed to reach the 50th percentile at least 
5 months before reaching the median. This further increases the bias described in this 
paper, especially when absolute benefit is quantified by a difference in medians from 
a BICR analysis and the experimental therapy is highly effective. A related issue can 
occur in advanced cancer studies, when a high proportion of patients, sometimes 
>50%, progress prior to the first scan. In this situation, while the BICR analysis may 
not be biased, the reported medians for both the local and BICR review can be highly 
dependent on the chosen assessment frequency.
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If there are problems with the median, it would be tempting to turn to alternative 
measures of average outcome, and in turn average benefit, such as landmark times, 
for example 1- or 2-year PFS or restricted mean survival [22]. However, as shown in 
Figure 1, the entire BICR survival curve can be exaggerated artificially increasing 
these other measures too.
In theory, the bias associated with informative censoring could be removed by 
requiring investigators to continue to scan patients until they have progressed 
according to the BICR, which would entail a real-time BICR review. This approach has 
proven successful in studies where patients can switch from control to the 
experimental arm [23], but only after central confirmation of progression. There are a 
number of practical and clinical issues that we believe are a major barrier to its routine 
use in a more general setting – it removes the responsibility for the care of patients by 
the treating physician and it should be considered whether the BICR assessment can 
be returned to the investigator sufficiently quickly. However, the development of 
immunotherapies and the possibility of pseudo progression has led to the idea of 
requiring a second scan to confirm progression [6]. If these confirmatory scans were 
consistently performed in both treatment arms, while not completely removing the bias 
caused by informative censoring, they would probably help to reduce its effect.
There are also broader implications for the findings presented in the paper. The 
median BICR PFS can cause confusion when presented alongside other endpoints.
For SOLO2 [13], the BICR median in the olaparib arm, 30.2 months, is longer than the 
median time to first subsequent therapy or death, 27.9 months, falsely implying that 
investigators added subsequent therapy prior to progression. Likewise, for NOVA [14]
the median PFS2 (the time to second progression according to local review), 25.8 m
14
in the niraparib arm, was only 4.8 m longer than the BICR median for PFS raising 
concerns that resistance to subsequent therapy had developed.
Finally, given the data presented in this paper, BICR PFS data should not be 
presented in isolation, either in publications or prescribing information even if it is 
designated as the primary endpoint; currently, this is not always the case. The olaparib 
prescribing information only contains the results of the local review for PFS, whereas 
for niraparib it only contains only the BICR review in platinum-sensitive ovarian cancer,
rendering any between-study comparison unreliable.
15
Key messages
• BICR may exaggerate PFS data including the median
• The HR remains the most reliable measure to describe the benefit of a BICR PFS 
analysis
• Further research is required to find better alternatives to more accurately 
estimate the survival curve for BICR PFS
• Presentation of data should routinely present the results of both the local and 
BICR evaluations
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Table 1. Simulated median local and BICR PFS according to correlation
a) No underlying bias: Median of 19 m with 12-week assessment frequency
Correlation True local 
median
Observed local 
median (5th, 95th 
percentile)
True BICR 
median
Observed BICR
median (5th, 95th 
percentile)
Local HR* BICR HR*
0.9 19.0 19.1 (16.3, 21.8) 19.0 24.8 (20.1, 30.1) 0.29 0.28
0.8 19.0 19.0 (16.3, 21.9) 19.1 24.5 (19.6, 30.0) 0.29 0.28
0.6 19.1 19.1 (16.3, 21.9) 19.1 22.3 (18.7, 27.5) 0.29 0.28
0.4 19.0 19.1 (16.3, 22.0) 19.1 20.9 (16.8, 25.1) 0.29 0.27
0.2 19.1 19.1 (16.2, 22.0) 19.0 19.3 (16.2, 22.7) 0.29 0.27
0 19.0 19.1 (16.3, 21.8) 19.1 17.5 (16.3, 21.8) 0.29 0.26
22
b) No underlying bias: Median of 6 m with 12-week assessment frequency
Correlation True local 
median
Observed local median
(5th, 95th percentile)
True BICR median Observed BICR median
(5th, 95th percentile)
0.9 6.0 6.0 (5.6, 7.8) 6.0 6.2 (5.6, 8.1)
0.8 6.0 6.0 (5.6, 7.8) 6.0 6.1 (5.6, 8.1)
0.6 6.0 6.0 (5.6, 7.7) 6.0 6.0 (5.5, 7.9)
0.4 6.0 6.0 (5.6, 7.8) 6.0 5.8 (5.4, 7.7)
0.2 6.0 6.0 (5.6, 7.8) 6.0 5.7 (5.3, 6.6)
0 6.0 6.0 (5.6, 7.8) 6.0 5.6 (5.2, 6.0)
1000 simulations of 200 patients per arm have been simulated. Data were simulated from bivariate normal distributions with the specified correlation 
coefficients and back transformed to create correlated exponential distributions with medians of 17.35 months panel a) and 5 months panel b).
Patients were assessed every 12 weeks and normally distributed variability was imposed around the intended timing with a standard deviation of 
23
0.5 months. The observed local PFS time was set at the time of the first visit occurring after the underlying local PFS time. The same approach was 
used to create observed BICR times, except that if the underlying BICR PFS time occurred later than the visit at which the local progression was 
detected, the BICR PFS time was censored at the time of local progression. This resulted in true medians of 19 and 6 months having aligned to 
visits. Finally, patients were assumed to enter the trial randomly over 15 months and a fixed minimum follow-up of 24 months was introduced, where 
patients who had not had an event by the end of the follow-up period were censored at their latest visit. This resulted in 70% and 98% maturity 
(events/patients) for local PFS with 19 and 6 months respectively.
*The HR compared PFS between panel a) and b) for the local and BICR data separately with the same correlation, where the true HR was 0.29.
Further details are provided in the supplementary appendix.
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Table 2. Hazard ratio and median PFS in maintenance trials of PARPi in 
platinum-sensitive BRCA-mutated ovarian cancer
Local BICR
Median HR (95% CI) Median HR (95% CI)
SOLO2 
(n=295)
19.1 v 5.5 0.30 
(0.22–0.41)
30.2 vs 5.5 0.25 
(0.18–0.35)
NOVA
(n=203)
14.8 v 5.5a 0.27 
(0.18–0.40)a
21.0 vs 5.5 0.27 
(0.17–0.41)
ARIEL3
(n=196)
16.6 v 5.4 0.23 
(0.16–0.34)
26.8 vs 5.4 0.20 
(0.13–0.32)
aData published in the FDA review [16]
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Figure legends
Figure 1. Estimated and true KM BICR curves
Curves displayed are for a correlation of 0.9 between BICR and local PFS times and a 12-week assessment 
frequency. True 6 m and True 19 m represent the KM curves for the true BICR PFS times having been aligned 
to visit with a 6 and 19 m median, respectively. Est 6 m and Est 19 m represent the corresponding BICR KM 
curves estimated in the presence of censoring
Figure 2. Kaplan-Meier curves for (a) olaparib, (b) niraparib and (c) rucaparib
(a) Reproduced with permission from Pujade-Lauraine et al. Olaparib tablets as maintenance therapy in 
patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): 
a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18(9):1274–1285 © 2017 
Elsevier Ltd. (b) Reproduced with permission from Mirza MR et al. Niraparib maintenance therapy in platinum-
sensitive, recurrent ovarian cancer. N Engl J Med 2016;375(22):2154–2164 © 2016 Massachusetts Medical 
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